The interim safety and efficacy data on OPN-305 (an Abzena inside programme in development by Opsona Therapeutics) in myelodysplastic syndrome is highly encouraging for the programme’s commercial potential, and provides further validation of Abzena’s Composite Human Antibody™ technology for safer antibodies. We are looking forward to the results from higher-dose cohorts in due course. We reiterate our positive stance on Abzena.
23 Nov 2016
N+1 Singer - Abzena - Positive Phase I/II data on Abzena inside programme OPN-305
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
N+1 Singer - Abzena - Positive Phase I/II data on Abzena inside programme OPN-305
Abzena (ABZA:LON) | 0 0 (-0.9%) | Mkt Cap: 54.0m
- Published:
23 Nov 2016 -
Author:
Dr Jens Lindqvist -
Pages:
3
The interim safety and efficacy data on OPN-305 (an Abzena inside programme in development by Opsona Therapeutics) in myelodysplastic syndrome is highly encouraging for the programme’s commercial potential, and provides further validation of Abzena’s Composite Human Antibody™ technology for safer antibodies. We are looking forward to the results from higher-dose cohorts in due course. We reiterate our positive stance on Abzena.